Other languages Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Real-time Estimate Cboe BZX Other stock markets 09:26:18 27/06/2024 pm IST			5-day change	1st Jan Change
2.125 ^USD	-3.41%		+10.94%	-69.22%

10/05	Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation	CI
09/05	Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation	10/05
Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment	30/04
Immix Biopharma, Inc. Announces on Track to Dose NXC-201 Patients in United States	18/04
Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03
Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial	20/03
Immix Biopharma Proposes Stock Offering; Shares Slump	06/02
Immix Biopharma, Inc. Announces New Clinical Data from Its Phase 1b/2a NEXICART-1	11/12
Immix Biopharma, Inc. to Host KOL Event to Discuss Its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis	22/11
GNW-Adhoc: Immix Biopharma gibt die FDA-Genehmigung des IND-Antrags für CAR-T NXC-201 bekannt, der die Verabreichung an US-Patienten ermöglicht	22/11
La FDA approuve le dossier d’essai clinique de Immix Biopharma CAR-T NXC-201, et en permet ainsi l’administration aux patients américains	22/11
Immix Biopharma gibt die FDA-Genehmigung des IND-Antrags für CAR-T NXC-201 bekannt, der die Verabreichung an US-Patienten ermöglicht	22/11
Immix Biopharma Says FDA Clears Investigational New Drug Application for NXC-201; Shares Fall	21/11
Immix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients	06/11
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site	16/23/16
Immix Biopharma, Inc. Announces Complete Response in 9Th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial At IMS 20Th Annual Meeting	03/23/03
Top Midday Gainers	02/23/02
Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma	02/23/02
Immix Biopharma Files Registration Statement on Behalf of Selling Stockholder	26/23/26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Other languages

Filters